Literature DB >> 10438499

Parathyroid hormone-(1-34) enhances aggrecan synthesis via an insulin-like growth factor-I pathway.

A K Harvey1, X P Yu, C A Frolik, S Chandrasekhar.   

Abstract

During endochondral bone formation, the growth plate chondrocytes proliferate, become hypertrophic, lose the cartilage phenotype, undergo mineralization, and provide a scaffold upon which subsequent longitudinal bone growth occurs. Parathyroid hormone (PTH), a calcium-regulating hormone, and parathyroid hormone-related peptide (PTHrP), which shares several properties with PTH, have profound effects on skeletal growth and new bone formation. In order to define further the mechanism by which PTH/PTHrP promotes the cartilage phenotype, chondrocytes isolated from the rib cages of developing rat embryos were evaluated for the biosynthesis of aggrecan. Cells treated with PTH-(1-34) for a 4-h period followed by a 20-h recovery period showed a significant increase in cartilage proteoglycan (aggrecan) synthesis in a dose-dependent manner. Only N-terminally intact PTH and PTHrP were effective in stimulating aggrecan synthesis. Addition of a neutralizing antibody to insulin-like growth factor-I (IGF-I) during PTH treatment resulted in the inhibition of PTH-stimulated aggrecan synthesis, whereas the addition of a neutralizing antibody to insulin-like growth factor-binding protein-2 (IGFBP-2) resulted in an increase in synthesis in both the control and PTH-treated cells. In addition, PTH treatment resulted in an increase in the mRNA for aggrecan, a reduction in IGFBP-3 mRNA, and no discernible changes in IGF-I mRNA levels, which was complemented by quantitative changes in IGFBP-3 and free IGF-I levels. The reciprocal relationship in the expression of aggrecan and IGFBP was further confirmed in chondrocytes from various gestational stages during normal development. Collectively, our results indicate that the effect of PTH may be mediated at least in part through the regulation of the IGF/IGFBP axis, by a decrease in the level of IGFBP-3, and an increase in free IGF-I levels. It is likely that the local increase in IGF-I may lead to an increase in cartilage type proteoglycan synthesis and maintenance of the cartilage phenotype. The consequence of the prolonged maintenance may be to halt mineralization while a new scaffolding is created.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10438499     DOI: 10.1074/jbc.274.33.23249

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  5 in total

1.  Supplementation of articular cartilage-derived chondroprogenitors with bone morphogenic protein-9 enhances chondrogenesis without affecting hypertrophy.

Authors:  Kawin Padmaja; Soosai Manickam Amirtham; Grace Rebekah; Solomon Sathishkumar; Elizabeth Vinod
Journal:  Biotechnol Lett       Date:  2022-08-03       Impact factor: 2.716

2.  Intermittent parathyroid hormone (1-34) supplementation of bone marrow stromal cell cultures may inhibit hypertrophy, but at the expense of chondrogenesis.

Authors:  Ena Music; Kathryn Futrega; James S Palmer; Mackenzie Kinney; Bill Lott; Travis J Klein; Michael R Doran
Journal:  Stem Cell Res Ther       Date:  2020-07-29       Impact factor: 6.832

3.  Anabolic effects of IGF-1 signaling on the skeleton.

Authors:  Candice G T Tahimic; Yongmei Wang; Daniel D Bikle
Journal:  Front Endocrinol (Lausanne)       Date:  2013-02-04       Impact factor: 5.555

4.  Continuous infusion of PTH1-34 delayed fracture healing in mice.

Authors:  Kiminori Yukata; Tsukasa Kanchiku; Hiroshi Egawa; Michihiro Nakamura; Norihiro Nishida; Takahiro Hashimoto; Hiroyoshi Ogasa; Toshihiko Taguchi; Natsuo Yasui
Journal:  Sci Rep       Date:  2018-09-04       Impact factor: 4.379

Review 5.  The Role of IGF/IGF-IR-Signaling and Extracellular Matrix Effectors in Bone Sarcoma Pathogenesis.

Authors:  George N Tzanakakis; Eirini-Maria Giatagana; Aikaterini Berdiaki; Ioanna Spyridaki; Kyoko Hida; Monica Neagu; Aristidis M Tsatsakis; Dragana Nikitovic
Journal:  Cancers (Basel)       Date:  2021-05-19       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.